Concepedia

Author

Paul Newbold

AstraZeneca (United Kingdom)

Also Known As

D. Parker, Newbold, P, P C H Newbold, P C Newbold, P NEWBOLD, P Newbold, P. C. H. NEWBOLD, P. C. H. Newbold, P. NEWBOLD, P. Newbold

151

Publications

8.8K

Citations

39

H-Index

117

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)Loughborough UniversityUniversity of LeicesterKing's College London
PN

About

Paul Newbold is an author at AstraZeneca (United Kingdom) specializing in medicine, immunology, and inflammation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

16

1K

2

Business

7

7

1.2K

3

Management

3

3

922

4

Education

1

1

598

5

Engineering

1

1

598

Paul Newbold

×

53

Publications

7.3K

Citations

34

H-Index

YearCitations

Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Mona Bafadhel, Susan McKenna, Sarah Terry,

American Journal of Respiratory and Critical Care Medicine

2011

1K

Forecasting Economic Time Series

Stephen J. Taylor, Clive W. J. Granger, Paul Newbold

Journal of the Operational Research Society

1979

1K

Statistics for Business and Economics.

R. P. Hope, Paul Newbold

Journal of the Royal Statistical Society Series C (Applied Statistics)

1988

820

Design and Analysis of Time-Series Experiments.

Paul Newbold, Gene V. Glass, Victor L. Willson,

Journal of the American Statistical Association

1976

598

Benralizumab for the Prevention of COPD Exacerbations

Gerard J. Criner, Bartolomé R. Celli, Christopher E. Brightling,

New England Journal of Medicine

2019

311

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

J. Mark FitzGerald, Eugene R. Bleecker, Andrew Menzies‐Gow,

The Lancet Respiratory Medicine

2017

309

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Bruce E. Sands, Jingjing Chen, Brian G. Feagan,

Gastroenterology

2017

273

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Eugene R. Bleecker, Michael E. Wechsler, J. Mark FitzGerald,

European Respiratory Journal

2018

237

Benralizumab for <i>PDGFRA</i> -Negative Hypereosinophilic Syndrome

Fei Li Kuang, Fanny Legrand, Michelle Makiya,

New England Journal of Medicine

2019

203

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

Tuyet‐Hang Pham, Gautam Damera, Paul Newbold,

Respiratory Medicine

2016

180

Page 1